Skip to main content

Table 2 Associations between NER genetic variants and DFS and OS of Chinese ESCC patients

From: Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy

NER genotypes No. of patients DFS OS
Progression Univariate analysis Multivariate analysis* Death Univariate analysis Multivariate analysis*
No. (%) HR (95 % CI) P value HR (95 % CI) P value No. (%) HR (95 % CI) P value HR (95 % CI) P value
ERCC5 rs2094258            
 CC 108 53 (49.1) 1.00   1.00   42 (38.9) 1.00   1.00  
 CT 181 128 (70.7) 1.78 (1.29–2.46) 0.0004 1.70 (1.23–2.36) 0.001 118 (65.2) 2.06 (1.45–2.93) <0.0001 1.98 (1.38–2.83) 0.0002
 TT 55 39 (70.9) 1.72 (1.14–2.61) 0.010 1.63 (1.07–2.48) 0.021 36 (65.5) 2.07 (1.32–2.23) 0.001 2.02 (1.29–3.16) 0.002
 CT+TT 236 167 (70.8) 1.76 (1.30–2.41) 0.0003 1.68 (1.23–2.31) 0.012 154 (65.3) 2.06 (1.46–2.90) <0.0001 1.99 (1.40–2.81) 0.0001
 Trend test     0.002   0.0007    0.0002   0.0005
 CC+CT 289 181 (62.6) 1.00   1.00   160 (55.4) 1.00   1.00  
 TT 55 39 (70.9) 1.19 (0.84–1.68) 0.331 1.16 (0.82–1.64) 0.415 36 (65.5) 1.28 (0.89–1.84) 0.178 1.29 (0.90–1.86) 0.171
ERCC5 rs2296147            
 TT 244 160 (65.6) 1.00   1.00   145 (59.4) 1.00   1.00  
 TC 91 56 (61.5) 0.91 (0.67–1.23) 0.524 0.91 (0.67–1.24) 0.563 49 (53.9) 0.87 (0.63–1.21) 0.411 0.92 (0.66–1.29) 0.603
 CC 9 4 (44.4) 0.52 (0.19–1.42) 0.201 0.49 (0.18–1.34) 0.165 2 (22.2) 0.26 (0.06–1.05) 0.058 0.27 (0.07–1.09) 0.066
 TC+CC 100 60 (60.0) 0.86 (0.64–1.16) 0.333 0.87 (0.64–1.17) 0.345 51 (51.0) 0.80 (0.58–1.10) 0.172 0.84 (0.61–1.16) 0.289
 Trend test     0.214   0.206    0.067   0.120
 TT+CT 335 216 (64.5) 1.00   1.00   194 (57.9) 1.00   1.00  
 CC 9 4 (4.4) 0.54 (0.20–1.45) 0.219 0.51 (0.19–1.37) 0.180 2 (22.2) 0.27 (0.07–1.08) 0.065 0.28 (0.07–1.12) 0.071
ERCC5 rs873601            
 AA 56 29 (51.8) 1.00     22 (39.3)     
 GA 189 126 (66.7) 1.58 (1.05–2.36) 0.027 1.63 (1.08–2.47) 0.021 112 (59.3) 1.83 (1.16–2.89) 0.010 1.89 (1.19–3.02) 0.008
 GG 99 65 (65.7) 1.56 (1.01–2.42) 0.047 1.51 (0.97–2.34) 0.069 62 (62.6) 1.99 (1.22–3.24) 0.006 1.93 (1.18–3.16) 0.009
 GA+GG 288 191 (66.3) 1.57 (1.06–2.32) 0.024 1.59 (1.06–2.37) 0.024 174 (39.3) 1.89 (1.21–2.94) 0.005 1.91 (1.21–2.99) 0.0005
 Trend test     0.084   0.146    0.011   0.021
 AA+GA 245 155 (63.3) 1.00     134 (54.7) 1.00    
 GG 99 65 (65.7) 1.09 (0.82–1.46) 0.536 1.04 (0.77–1.39) 0.803 62 (62.6) 1.23 (0.91–1.67) 0.168 1.18 (0.87–1.60) 0.297
ERCC2 rs238406            
 GG 102 58 (56.9) 1.00   1.00   50 (49.0) 1.00   1.00  
 GT 158 101 (63.9) 1.16 (0.84–1.61) 0.361 1.15 (0.83–1.60) 0.403 87 (55.1) 1.21 (0.85–1.71) 0.256 1.23 (0.87–1.75) 0.247
 TT 84 61 (72.6) 1.59 (1.11–2.28) 0.012 1.56 (1.08–2.24) 0.017 59 (70.2) 1.76 (1.21–2.57) 0.003 1.72 (1.18–2.52) 0.005
 GT+TT 242 162 (66.9) 1.29 (0.96–1.75) 0.094 1.28 (0.94–1.73) 0.115 146 (60.3) 1.38 (1.00–1.91) 0.049 1.40 (1.01–1.93) 0.044
 Trend test     0.013   0.019    0.004   0.005
 GG+GT 260 159 (61.2) 1.00   1.00   137 (52.7) 1.00   1.00  
 TT 84 61 (72.6) 1.45 (1.08–1.95) 0.014 1.43 (1.06–1.93) 0.020 59 (70.2) 1.57 (1.15–2.13) 0.004 1.52 (1.12–2.03) 0.008
XPC rs1870134            
 GG 181 111 (61.3)      94 (51.9) 1.00   1.00  
 GC 144 95 (66.0) 1.08 (0.82–1.41) 0.605 1.10 (0.83–1.46) 0.495 89 (61.8) 1.21(0.91–1.62) 0.192 1.25 (0.93–1.68) 0.137
 CC 18 14 (73.7) 1.67 (0.96–2.92) 0.070 1.41 (0.80–2.48) 0.235 13 (68.4) 1.77 (0.99–3.17) 0.053 1.52 (0.84–2.75) 0.164
 GC+CC 163 109 (66.9) 1.13 (0.87–1.47) 0.374 1.13 (0.87–1.48) 0.356 102 (62.6) 1.26 (0.96–1.67) 0.101 1.28 (0.96–1.70) 0.088
 Trend test     0.171   0.242    0.045   0.066
 GG+GC 325 206 (63.4) 1.00   1.00   183 (56.3) 1.00   1.00  
 CC 19 14 (73.7) 1.62 (0.94–2.79) 0.081 1.35 (0.78–2.35) 0.285 13 (68.4) 1.62 (0.92–2.85) 0.093 1.38 (0.78–2.45) 0.274
XPC rs2228001            
 TT 139 87 (62.6) 1.00   1.00   77 (55.4) 1.00   1.00  
 TG 155 101 (65.2) 1.10 (0.82–1.46) 0.537 1.19 (0.89–1.59) 0.250 89 (57.4) 1.05 (0.77–1.42) 0.758 1.15 (0.84–1.57) 0.377
 GG 50 32 (64.0) 1.18 (0.79–1.77) 0.418 1.29 (0.85–1.96) 0.238 30 (60.0) 1.25 (0.82–1.91) 0.295 1.36 (0.88–2.12) 0.171
 TG+GG 205 133 (64.9) 1.12 (0.85–1.46) 0.432 1.21 (0.92–1.59) 0.181 119 (58.0) 1.09 (0.82–1.46) 0.539 1.19 (0.89–1.60) 0.241
 Trend test     0.713   0.593    0.386   0.282
 TT+TG 294 188 (64.0) 1.00   1.00   166 (56.5) 1.00   1.00  
 GG 50 32 (64.0) 0.89 (0.61–1.29) 0.531 1.17 (0.80–1.73) 0.418 30 (60.0) 1.22 (0.83–1.80) 0.313 1.26 (0.84–1.89) 0.263
NRG**            
 0 37 18 (48.7) 1.00   1.00   12 (32.4) 1.00   1.00  
 1 63 30 (47.6) 0.97 (0.54–1.17) 0.789 1.09 (0.60–1.98) 0.920 25 (39.7) 1.22 (0.61–1.42) 0.578 1.38 (0.69–2.79) 0.365
 2 187 127 (67.9) 1.32 (1.03–1.69) 0.030 1.32 (1.03–1.71) 0.021 115 (61.5) 1.53 (1.14–2.06) 0.005 1.55 (1.15–2.10) 0.005
 3 57 45 (79.0) 1.34 (1.12–1.61) 0.002 1.34 (1.11–1.61) 0.0009 44 (77.2) 1.51 (1.22–1.87) <0.0002 1.51 (1.22–1.88) 0.0002
 Trend test     <0.0001   <0.0001    <0.0001   <0.0001
 0–1 100 48 (48.0) 1.00   1.00   37 (37.0) 1.00   1.00  
 2–3 244 172 (70.5) 1.69 (1.22–2.35) 0.002 1.67 (1.20–2.34) 0.003 159 (65.2) 1.84 (1.32–2.58) 0.0004 1.77 (1.29–2.50) 0.001
  1. * Adjusted by all the demographic and clinical variables in Table 1 including age, sex, smoking, drinking, TNM stage, vessel invasion, neural invasion, lymphadenectomy
  2. ** NRG include ERCC5 rs2094258 CT/TT, re873061GA/GG, ERCC2 rs238406 TT